Advanced stage lung cancer: Persisting challenges in the era of molecular targeted therapy-our experience

Srinidhi Govindarajan, Deepa Sa Adiga, Flora D. Lobo, Ranjitha Rao, Krishna Prasad, Chaithra Gowthuvalli Venkataramanna

Research output: Contribution to journalArticle

Abstract

Introduction: Lung cancer is the pioneer among all the cancers and also the leading cause of cancer related mortality worldwide. In India unlike in western countries most patients are diagnosed at advanced stage (Stage III/Stage IV) which in turn adversely affects the patient prognosis and survival. Studying the proportion of the total lung cancer cases which will present in advanced stage and their clinical, pathological and radiological profile will give us an insight into the problem. Aim: To know the percentage incidence of patients presenting with advanced stage lung cancer (Stage IIIB/Stage IV) and to study the clinical, pathological and radiological profile of these patients along with treatment details and follow-up. Materials and Methods: This was a descriptive retrospective study spanning 4 years from January 2013 to December 2016. All patients with a histopathological diagnosis of Stage IIIB and Stage IV lung cancer, treated during this period were included. Clinical features, radiological (X-ray and CT) findings, histopathological findings including immunohistochemistry if done, treatment modality and survival were analysed based on the information collected from the medical records. results: Out of 82 cases diagnosed as advanced stage disease, complete clinical data was available for 67 cases which formed the material for the study. Of 67 patients, 47 were male and 20 were female forming a Male: Female ratio of 2.35:1. The mean age of the patients was 61.3 years. Patients presented with cough (59.7%), chest pain (34.3%) dyspnoea (29.8%), weight loss (17.9%), fever (16.4%), haemoptysis (11.9%). Histologically majority were Adenocarcinoma (ADC) (35.8%) followed by Squamous Cell Carcinoma (SCC) (29.8%) small cell carcinoma (14.92%) and just one case of large cell carcinoma. Forty three cases (64.17%) presented with metastases. The most common site for metastasis was bone followed by brain. Three patients who tested positive for Epidermal Growth Factor Receptor (EGFR) mutation were treated with Erlotinib/Gefitinib. The remaining 64 cases were treated with regimens including combinations of premetrexed, platinum based compounds and etoposide. On follow-up 17 patients died during the course of the treatment. conclusion: High proportion of lung cancer patients present at advanced stage. This demand for public awareness programs about the smoking hazards, early symptoms and importance of early treatment.

LanguageEnglish
PagesEC14-EC17
JournalJournal of Clinical and Diagnostic Research
Volume12
Issue number5
DOIs
Publication statusPublished - 01-05-2018

Fingerprint

Molecular Targeted Therapy
Lung Neoplasms
Cells
Etoposide
Platinum
Epidermal Growth Factor Receptor
Brain
Hazards
Bone
X rays
Platinum Compounds
Neoplasm Metastasis
Large Cell Carcinoma
Small Cell Carcinoma
X Ray Computed Tomography
Survival
Hemoptysis
Therapeutics
Chest Pain
Cough

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Govindarajan, Srinidhi ; Adiga, Deepa Sa ; Lobo, Flora D. ; Rao, Ranjitha ; Prasad, Krishna ; Venkataramanna, Chaithra Gowthuvalli. / Advanced stage lung cancer : Persisting challenges in the era of molecular targeted therapy-our experience. In: Journal of Clinical and Diagnostic Research. 2018 ; Vol. 12, No. 5. pp. EC14-EC17.
@article{65e989d5504c4a74b77bbf257d602177,
title = "Advanced stage lung cancer: Persisting challenges in the era of molecular targeted therapy-our experience",
abstract = "Introduction: Lung cancer is the pioneer among all the cancers and also the leading cause of cancer related mortality worldwide. In India unlike in western countries most patients are diagnosed at advanced stage (Stage III/Stage IV) which in turn adversely affects the patient prognosis and survival. Studying the proportion of the total lung cancer cases which will present in advanced stage and their clinical, pathological and radiological profile will give us an insight into the problem. Aim: To know the percentage incidence of patients presenting with advanced stage lung cancer (Stage IIIB/Stage IV) and to study the clinical, pathological and radiological profile of these patients along with treatment details and follow-up. Materials and Methods: This was a descriptive retrospective study spanning 4 years from January 2013 to December 2016. All patients with a histopathological diagnosis of Stage IIIB and Stage IV lung cancer, treated during this period were included. Clinical features, radiological (X-ray and CT) findings, histopathological findings including immunohistochemistry if done, treatment modality and survival were analysed based on the information collected from the medical records. results: Out of 82 cases diagnosed as advanced stage disease, complete clinical data was available for 67 cases which formed the material for the study. Of 67 patients, 47 were male and 20 were female forming a Male: Female ratio of 2.35:1. The mean age of the patients was 61.3 years. Patients presented with cough (59.7{\%}), chest pain (34.3{\%}) dyspnoea (29.8{\%}), weight loss (17.9{\%}), fever (16.4{\%}), haemoptysis (11.9{\%}). Histologically majority were Adenocarcinoma (ADC) (35.8{\%}) followed by Squamous Cell Carcinoma (SCC) (29.8{\%}) small cell carcinoma (14.92{\%}) and just one case of large cell carcinoma. Forty three cases (64.17{\%}) presented with metastases. The most common site for metastasis was bone followed by brain. Three patients who tested positive for Epidermal Growth Factor Receptor (EGFR) mutation were treated with Erlotinib/Gefitinib. The remaining 64 cases were treated with regimens including combinations of premetrexed, platinum based compounds and etoposide. On follow-up 17 patients died during the course of the treatment. conclusion: High proportion of lung cancer patients present at advanced stage. This demand for public awareness programs about the smoking hazards, early symptoms and importance of early treatment.",
author = "Srinidhi Govindarajan and Adiga, {Deepa Sa} and Lobo, {Flora D.} and Ranjitha Rao and Krishna Prasad and Venkataramanna, {Chaithra Gowthuvalli}",
year = "2018",
month = "5",
day = "1",
doi = "10.7860/JCDR/2018/35799.11481",
language = "English",
volume = "12",
pages = "EC14--EC17",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "5",

}

Advanced stage lung cancer : Persisting challenges in the era of molecular targeted therapy-our experience. / Govindarajan, Srinidhi; Adiga, Deepa Sa; Lobo, Flora D.; Rao, Ranjitha; Prasad, Krishna; Venkataramanna, Chaithra Gowthuvalli.

In: Journal of Clinical and Diagnostic Research, Vol. 12, No. 5, 01.05.2018, p. EC14-EC17.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advanced stage lung cancer

T2 - Journal of Clinical and Diagnostic Research

AU - Govindarajan, Srinidhi

AU - Adiga, Deepa Sa

AU - Lobo, Flora D.

AU - Rao, Ranjitha

AU - Prasad, Krishna

AU - Venkataramanna, Chaithra Gowthuvalli

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Introduction: Lung cancer is the pioneer among all the cancers and also the leading cause of cancer related mortality worldwide. In India unlike in western countries most patients are diagnosed at advanced stage (Stage III/Stage IV) which in turn adversely affects the patient prognosis and survival. Studying the proportion of the total lung cancer cases which will present in advanced stage and their clinical, pathological and radiological profile will give us an insight into the problem. Aim: To know the percentage incidence of patients presenting with advanced stage lung cancer (Stage IIIB/Stage IV) and to study the clinical, pathological and radiological profile of these patients along with treatment details and follow-up. Materials and Methods: This was a descriptive retrospective study spanning 4 years from January 2013 to December 2016. All patients with a histopathological diagnosis of Stage IIIB and Stage IV lung cancer, treated during this period were included. Clinical features, radiological (X-ray and CT) findings, histopathological findings including immunohistochemistry if done, treatment modality and survival were analysed based on the information collected from the medical records. results: Out of 82 cases diagnosed as advanced stage disease, complete clinical data was available for 67 cases which formed the material for the study. Of 67 patients, 47 were male and 20 were female forming a Male: Female ratio of 2.35:1. The mean age of the patients was 61.3 years. Patients presented with cough (59.7%), chest pain (34.3%) dyspnoea (29.8%), weight loss (17.9%), fever (16.4%), haemoptysis (11.9%). Histologically majority were Adenocarcinoma (ADC) (35.8%) followed by Squamous Cell Carcinoma (SCC) (29.8%) small cell carcinoma (14.92%) and just one case of large cell carcinoma. Forty three cases (64.17%) presented with metastases. The most common site for metastasis was bone followed by brain. Three patients who tested positive for Epidermal Growth Factor Receptor (EGFR) mutation were treated with Erlotinib/Gefitinib. The remaining 64 cases were treated with regimens including combinations of premetrexed, platinum based compounds and etoposide. On follow-up 17 patients died during the course of the treatment. conclusion: High proportion of lung cancer patients present at advanced stage. This demand for public awareness programs about the smoking hazards, early symptoms and importance of early treatment.

AB - Introduction: Lung cancer is the pioneer among all the cancers and also the leading cause of cancer related mortality worldwide. In India unlike in western countries most patients are diagnosed at advanced stage (Stage III/Stage IV) which in turn adversely affects the patient prognosis and survival. Studying the proportion of the total lung cancer cases which will present in advanced stage and their clinical, pathological and radiological profile will give us an insight into the problem. Aim: To know the percentage incidence of patients presenting with advanced stage lung cancer (Stage IIIB/Stage IV) and to study the clinical, pathological and radiological profile of these patients along with treatment details and follow-up. Materials and Methods: This was a descriptive retrospective study spanning 4 years from January 2013 to December 2016. All patients with a histopathological diagnosis of Stage IIIB and Stage IV lung cancer, treated during this period were included. Clinical features, radiological (X-ray and CT) findings, histopathological findings including immunohistochemistry if done, treatment modality and survival were analysed based on the information collected from the medical records. results: Out of 82 cases diagnosed as advanced stage disease, complete clinical data was available for 67 cases which formed the material for the study. Of 67 patients, 47 were male and 20 were female forming a Male: Female ratio of 2.35:1. The mean age of the patients was 61.3 years. Patients presented with cough (59.7%), chest pain (34.3%) dyspnoea (29.8%), weight loss (17.9%), fever (16.4%), haemoptysis (11.9%). Histologically majority were Adenocarcinoma (ADC) (35.8%) followed by Squamous Cell Carcinoma (SCC) (29.8%) small cell carcinoma (14.92%) and just one case of large cell carcinoma. Forty three cases (64.17%) presented with metastases. The most common site for metastasis was bone followed by brain. Three patients who tested positive for Epidermal Growth Factor Receptor (EGFR) mutation were treated with Erlotinib/Gefitinib. The remaining 64 cases were treated with regimens including combinations of premetrexed, platinum based compounds and etoposide. On follow-up 17 patients died during the course of the treatment. conclusion: High proportion of lung cancer patients present at advanced stage. This demand for public awareness programs about the smoking hazards, early symptoms and importance of early treatment.

UR - http://www.scopus.com/inward/record.url?scp=85047159375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047159375&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2018/35799.11481

DO - 10.7860/JCDR/2018/35799.11481

M3 - Article

VL - 12

SP - EC14-EC17

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 5

ER -